Post by jinathjemi22222 on Feb 25, 2024 0:26:41 GMT -8
German government ministers have reacted furiously to reports that the Trump administration has attempted to buy exclusive rights to a coronavirus vaccine being developed by a German company. An explosive report in German newspaper Welt cites German government sources as saying that the Trump administration offered "$1 billion" to secure exclusive rights to a coronavirus vaccine being developed by the company CureVac, "but only for the US." "U.S." The German Health Ministry has confirmed to Reuters the veracity of the information: "We confirmed the news in the Welt ," said a representative.
Following the news, German Foreign Minister Heiko Maas has insisted that the government would not allow President Donald Trump to go ahead with his plan. "German researchers play an important role in the development of drugs and vaccines, and we cannot allow others to seek exclusive results," Funke assured the group . Read more: China and the United States are going to begin C Level Contact List testing the first experimental vaccines in humans against coronavirus in the race to find a cure "Germany is not for sale," the country's economy minister, Peter Altmaier, confirmed to the ARD radio station , according to AFP. Karl Lauterbach, a senior German politician and professor of health economics and epidemiology, tweeted in response to the story: "The exclusive sale of a possible vaccine to the United States must be avoided by all means.
Capitalism has limits." . A US official told AFP that the information has been "grossly exaggerated", and has denied that a vaccine would be exclusive to the United States. "We will continue to talk to any company that claims to be able to help. And any solution found will be shared with the world," the spokesperson said. Florian von der Muelbe, head of production and co-founder of CureVac, told Reuters last week that the company hoped to have an experimental vaccine ready by June or July so it could apply for permission to begin human trials. He said the vaccine the company hoped to develop could be suitable for mass production within CureVac's existing facilities.